This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Response Genetics Announces Presentation Of Lung Cancer And Esophageal Cancer Study Results At 2011 American Society Of Clinical Oncology Annual Meeting

Monday June 6, 5:00 p.m. to 6:00 p.m. CT, Hall D2

Abstract No. 7530: Use of negative TTF-1 status to predict for negative EGFR mutations status with a high negative predictive value in patients with adenocarcinomas of the lung.

Archival specimens from patients with NSCLC were tested for EGFR mutations by allele-specific PCR; TTF-1 status was determined by examining patients’ pathology reports. Of the 693 specimens tested, TTF-1 status was known in 301, and of those, 224 (74 percent) harbored EGFR mutations – only two of the EGFR mutation-positive specimens were TTF-1 negative and 28 of the 77 EGFR wild type specimens were TTF-1 negative. As TTF-1-negative lung adenocarcinomas have a 99 percent probability of also being negative for EGFR mutations, results suggest the benefit of initiating chemotherapy treatment in the 30 percent of patients who test positive for TTF-1 as their EGFR mutation status is verified.

Monday June 6, 5:00 p.m. to 6:00 p.m. CT, Hall D1

Abstract No. 4023: Association of ERCC1 gene expression with outcome in stage II-III esophageal adenocarcinoma patients treated with preoperative platinum-based chemoradiation in a phase II cooperative group study (SWOG S0356).

Expression of genes associated with drug metabolism (DPD, GSTPi, TS and TP) and DNA repair (ERCC1 and XPD) were tested to determine their association with clinical outcome in esophageal cancer. Thirteen polymorphisms in drug metabolism (GSTP, MTHFR and TS) and DNA repair (ERCC1, RAD51, XPD, XRCC1 and XRCC3) genes were also investigated to determine if specific patterns were predictive. In a univariate analysis of data derived from 92 patients, only ERCC1 gene expression levels were associated significantly with progression-free survival and overall survival, with high ERCC1 levels were predictive of lower two-year progression-free survival (17 versus 67 percent, p=0.0058) and two-year overall survival (37 versus 72 percent, p=0.047) compared to low levels. ERCC1 levels were not associated with complete pathologic response. These data suggest that assessing ERCC1 levels can help identify patients with stage II-III esophageal adenocarcinomas that are likely to experience longer survival when treated with preoperative oxaliplatin-based chemoradiation.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs